Stability of plasmid and viral banks supporting the cGMP manufacture of Q-Griffithsin from a TMV-based viral vector.

The "whole genome" TMV-based expression system, Geneware®, was used in the cGMP production of the plant-made pharmaceutical Q-Griffithsin and demonstrates stable expression for up to a two-year period. Virion and plasmid banks which contained viral cDNA and a Q-Griffithsin sequence were able to produce >200 g of Q-Griffithsin. Data assessing the quality and stability of the product banks were measured through functional assessments of visual symptomology and product expression.
Competing Interests: Declaration of Competing Interest KEP, JLF, and KTH are inventors on patents and patent applications that claim Q-GRFT composition and utility. In addition, KEP, JLF, and KTH are founders and equity holders in GROW Biomedicine LLC, which is commercializing Q-GRFT. EH, JMC, JWS declare no conflicts of interest.
(Copyright © 2020 Elsevier B.V. All rights reserved.)